These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38124475)

  • 1. Liver transplantation and hepatocellular carcinoma 2023: a narrative review of management and outcomes.
    Tabrizian P; Holzner ML; Zaret D; Meyerovich G; Fagenson A; Schiano T
    Ann Palliat Med; 2024 Jan; 13(1):126-140. PubMed ID: 38124475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
    Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
    Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current controversies surrounding liver transplantation for hepatocellular carcinoma.
    Silva MF; Wigg AJ
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1217-26. PubMed ID: 20594247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.
    Rich NE; Parikh ND; Singal AG
    Curr Treat Options Gastroenterol; 2017 Jun; 15(2):296-304. PubMed ID: 28425018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
    Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
    Silverstein J; Roll G; Dodge JL; Grab JD; Yao FY; Mehta N
    Liver Transpl; 2020 Sep; 26(9):1100-1111. PubMed ID: 32531867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
    Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
    World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma.
    Rudnick SR; Russo MW
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):265-275. PubMed ID: 29231769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
    Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
    Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.